Rubius Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Craig Jalbert

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	no data
Board average tenure	2.4yrs

Recent management updates

Recent updates

CEO

Craig Jalbert (61 yo)

less than a year

Tenure

Mr. Craig R. Jalbert, CIRA serves as Director at Oncorus, Inc. since July 28, 2023 and serves as Chief Executive Officer, President, Chief Financial Officer, Treasurer and Secretary from August 4, 2023. He...

Board Members

Name	Position	Tenure	Compensation	Ownership
Craig Jalbert	President	less than a year	no data	no data
Michael Rosenblatt	Independent Director	8.8yrs	US$421.66k	no data
Robert Langer	Member of Scientific Advisory Board	8.8yrs	US$850.74k	no data
Harvey Lodish	Scientific Advisory Board	5.7yrs	US$24.00k	no data
Gerald Nepom	Member of Scientific Advisory Board	2.4yrs	no data	no data
Vijay Kuchroo	Member of Scientific Advisory Board	2.4yrs	no data	no data
Susanne Schaffert	Director	1.3yrs	no data	no data
Francis Cuss	Independent Director	5.8yrs	US$426.66k	no data
Christopher Carpenter	Member of Scientific Advisory Board	3.8yrs	US$2.84m	no data
Christopher Hunter	Member of Scientific Advisory Board	2.4yrs	no data	no data
John Monroe	Member of Scientific Advisory Board	2.4yrs	no data	no data

2.4yrs

Average Tenure

68yo

Average Age

Experienced Board: 5RT's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/10/07 15:43
End of Day Share Price	2023/10/05 00:00
Earnings	2022/12/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rubius Therapeutics, Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Michael Schmidt	Guggenheim Securities, LLC
Andrew Fein	H.C. Wainwright & Co.
Michael Yee	Jefferies LLC